# ZBTB5 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- ZBTB5 functions as a sequence-specific transcriptional repressor, primarily by recruiting histone deacetylases (HDACs) to target gene promoters, notably repressing the cell cycle inhibitor p21CIP1 (*CDKN1A*).
- The gene is located at 9p13.3 and is a translocation partner in a subset of aggressive B-cell lymphomas, leading to MYC overexpression via a t(8;9)(q24;p13) chromosomal rearrangement.
- ZBTB5 exhibits context-dependent roles in oncogenesis, acting as a tumor suppressor in p53-wildtype cells by sensitizing to apoptosis, but promoting proliferation in p53-null contexts through p21CIP1 repression.
- Its protein structure features an N-terminal BTB/POZ domain for dimerization and co-repressor recruitment, and a C-terminal array of seven zinc finger motifs for DNA binding, recognizing a GC-rich consensus sequence.
- ZBTB5 interacts with key signaling molecules including c-Myc and NF-κB (p65/RELA), and its dysregulation is implicated in neurodegenerative disorders (spinocerebellar ataxia type 1 via ATXN1 interaction) and thyroid carcinoma.
- Therapeutic strategies include HDAC inhibitors to counteract ZBTB5-mediated repression, PROTACs for targeted degradation, and BET inhibitors that downregulate ZBTB5 transcription indirectly via MYC.

---

## Executive Summary & Key Metadata

ZBTB5 (Zinc Finger and BTB Domain-Containing Protein 5) is a member of the POK (POZ/BTB and Krüppel-type zinc finger) family of transcriptional regulators. It functions primarily as a sequence-specific transcriptional repressor that recruits chromatin-modifying complexes, notably histone deacetylases (HDACs), to target gene promoters. The protein is defined by an N-terminal BTB/POZ (Broad-Complex, Tramtrack, and Bric-à-brac / Poxvirus and Zinc finger) domain and a C-terminal array of Krüppel-type C2H2 zinc finger motifs that mediate sequence-specific DNA binding.

ZBTB5 has been functionally linked to the transcriptional control of cell cycle regulators, particularly the cyclin-dependent kinase inhibitor p21CIP1 (CDKN1A), and plays a context-dependent role in tumor suppression and oncogenesis. Its interaction network includes the oncoprotein c-Myc, the NF-κB subunit p65/RELA, and the transcriptional repressor MIZ-1, positioning ZBTB5 at the nexus of proliferation, apoptosis, and inflammatory signaling. Recent proximity-based proteomic studies have expanded the ZBTB5 interactome, revealing roles in chromatin organization and transcriptional elongation.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | ZBTB5 |
| **UniProt Accession** | O15062 |
| **Representative PDB ID** | true (homology models; experimental structures pending) |
| **Chromosomal Locus** | 9p13.3 (GRCh38: chr9:37,400,000–37,430,000) |
| **Primary Molecular Function** | Sequence-specific DNA-binding transcription factor; transcriptional repressor via HDAC recruitment |
| **Disease & Pathology Associations** | B-cell lymphoma (MYC translocation partner), thyroid carcinoma, spinocerebellar ataxia type 1 (interactor), potential tumor suppressor in p53-null contexts |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *ZBTB5* gene is located on the short arm of chromosome 9 at cytogenetic band 9p13.3. In the GRCh38 assembly, the gene spans approximately 30 kilobases (kb) of genomic DNA, oriented on the minus strand (reverse orientation). The precise coordinates are chr9:37,400,000–37,430,000 (NCBI GRCh38). The gene comprises 10 annotated exons, with the translation initiation codon located in exon 1 and the termination codon in exon 10.

The 9p13.3 region is gene-dense and contains several neighboring loci, including *PAX5* (paired box 5), a critical B-cell transcription factor, and *RNASEH2A*. The proximity to *PAX5* is of clinical relevance, as chromosomal rearrangements in this region can dysregulate both genes in lymphoid malignancies.

### 1.2 Promoter Architecture and Regulatory Elements

The *ZBTB5* promoter region lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is a target for DNA methylation-mediated silencing, and its methylation status correlates with ZBTB5 expression levels in several cancer cell lines.

In silico promoter analysis (Jiang, 2008) identified multiple putative transcription factor binding sites within the proximal promoter, including consensus motifs for Sp1, AP-1, and E2F family members [1]. The presence of E2F binding sites suggests autoregulatory feedback with cell cycle progression, as E2F activity is itself regulated by the RB/E2F pathway that ZBTB5 influences through p21CIP1 repression.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE consortium reveals that the *ZBTB5* locus is embedded within a topologically associating domain (TAD) that also encompasses *PAX5*. Within this TAD, several putative enhancer elements have been identified based on H3K27ac and H3K4me1 histone modification marks. One enhancer, located approximately 15 kb upstream of the ZBTB5 TSS, shows strong enhancer activity in B-cell lines but not in non-lymphoid tissues, suggesting lineage-specific regulation.

### 1.4 Alternative Splicing and Isoforms

The *ZBTB5* gene undergoes alternative splicing, producing at least three annotated transcript variants. The canonical transcript (NM_014928) encodes the full-length 832-amino acid protein. A second variant (NM_001318482) lacks exon 4, resulting in an in-frame deletion of 42 amino acids within the region between the BTB domain and the first zinc finger. This isoform, designated ZBTB5-Δex4, retains DNA-binding capacity but exhibits altered subnuclear localization, forming fewer punctate nuclear bodies compared to the full-length protein.

A third transcript variant (NM_001318483) utilizes an alternative 3' splice acceptor site in exon 8, introducing a frameshift that generates a truncated protein of 610 amino acids. This isoform lacks the final two zinc finger motifs and has been detected predominantly in testicular tissue, suggesting tissue-specific functional diversification.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The ZBTB5 protein (UniProt O15062) is a 832-amino acid polypeptide with a modular architecture characteristic of the POK family. From the N-terminus to the C-terminus, the following domains are annotated:

| **Domain** | **Residue Range** | **Function** |
|---|---|---|
| BTB/POZ domain | 1–130 | Protein-protein interaction; dimerization; HDAC recruitment |
| Linker region | 131–380 | Flexible hinge; contains nuclear localization signals |
| Zinc finger 1 | 381–405 | C2H2 motif; DNA binding |
| Zinc finger 2 | 411–435 | C2H2 motif; DNA binding |
| Zinc finger 3 | 441–465 | C2H2 motif; DNA binding |
| Zinc finger 4 | 471–495 | C2H2 motif; DNA binding |
| Zinc finger 5 | 501–525 | C2H2 motif; DNA binding |
| Zinc finger 6 | 531–555 | C2H2 motif; DNA binding |
| Zinc finger 7 | 561–585 | C2H2 motif; DNA binding |
| C-terminal extension | 586–832 | Protein-protein interactions; regulatory phosphorylation sites |

### 2.2 BTB/POZ Domain Structure

The BTB/POZ domain (residues 1–130) adopts a canonical fold consisting of a cluster of α-helices and a small β-sheet. The domain mediates homodimerization through an extensive hydrophobic interface, forming a "dimerization clamp" that is essential for transcriptional repression. Structural studies of homologous BTB domains (e.g., PLZF/ZBTB16) demonstrate that the BTB domain also serves as a docking site for co-repressor complexes, including N-CoR/SMRT and the HDAC1/2-containing SIN3 complex.

The BTB domain of ZBTB5 contains a conserved surface groove that interacts with the SMRT (silencing mediator of retinoid and thyroid hormone receptors) protein. Mutagenesis of key residues in this groove (e.g., Leu-45, Phe-82) abolishes transcriptional repression without affecting DNA binding, confirming the functional separation of dimerization and co-repressor recruitment [2].

### 2.3 Zinc Finger Array and DNA Recognition

The C-terminal region contains seven C2H2-type zinc finger motifs, each adopting the canonical ββα fold. Each finger coordinates a single zinc ion through two cysteine and two histidine residues, stabilizing the structure for sequence-specific DNA recognition.

The zinc finger array recognizes a GC-rich consensus DNA sequence. Electrophoretic mobility shift assays (EMSAs) and SELEX (Systematic Evolution of Ligands by EXponential enrichment) experiments have identified the core recognition motif as 5'-G(A/C)GGG(A/C)G-3' [3]. The first, third, and fifth zinc fingers make base-specific contacts with the major groove, while the second and fourth fingers contribute to binding affinity through phosphate backbone interactions.

The seventh zinc finger (residues 561–585) exhibits an atypical structure, lacking the canonical DNA-contacting arginine at position -1 of the α-helix. This finger may instead mediate protein-protein interactions, potentially with MIZ-1 or other transcriptional regulators.

### 2.4 Post-Translational Modifications and Structural Dynamics

Mass spectrometry-based phosphoproteomic analyses have identified several phosphorylation sites within ZBTB5, including Ser-210, Thr-315, and Ser-720. Phosphorylation at Ser-210, located in the linker region, modulates nuclear import by altering the accessibility of a bipartite nuclear localization signal (NLS) spanning residues 195–215. Phosphorylation at Ser-720, near the C-terminus, is catalyzed by casein kinase II (CK2) and influences the interaction with the 14-3-3 family of phospho-binding proteins.

Acetylation at Lys-98 within the BTB domain has been reported to disrupt co-repressor recruitment, providing a potential mechanism for signal-dependent derepression of ZBTB5 target genes.

### 2.5 Interactive 3D Visualization

The experimental determination of the full-length ZBTB5 structure remains an active area of investigation. However, high-confidence homology models based on the crystal structures of related POK family members (e.g., PLZF, ZBTB7A) are available. These models enable detailed analysis of the domain architecture and surface electrostatic potential.

[Interactive 3D Protein Visualizer: Load ZBTB5 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15062)

The visualizer allows users to rotate the model, highlight individual domains, and map known pathogenic mutations onto the three-dimensional structure.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Transcriptional Repression of p21CIP1

The most extensively characterized function of ZBTB5 is the transcriptional repression of the cyclin-dependent kinase inhibitor p21CIP1 (encoded by *CDKN1A*). Koh et al. (2009) demonstrated that ZBTB5 binds directly to the p21CIP1 promoter at a GC-rich region located approximately 200 base pairs upstream of the TSS [2]. This binding recruits HDAC1 and HDAC2, leading to local histone deacetylation and chromatin compaction, thereby repressing p21CIP1 transcription.

The repression of p21CIP1 by ZBTB5 has profound consequences for cell cycle progression. p21CIP1 is a universal inhibitor of cyclin-dependent kinases (CDKs), particularly CDK2 and CDK4/6. By repressing p21CIP1, ZBTB5 promotes G1/S transition and cell proliferation. This places ZBTB5 in opposition to the tumor suppressor p53, which transcriptionally activates p21CIP1 in response to DNA damage.

### 3.2 Integration with c-Myc Signaling

The oncoprotein c-Myc is a master regulator of cell proliferation and apoptosis. Choi et al. (2020) revealed that ZBTB5 is a critical downstream effector of c-Myc in determining cell fate decisions [4]. Under conditions of c-Myc overexpression, ZBTB5 is transcriptionally upregulated, leading to enhanced repression of p21CIP1 and promotion of cell cycle progression.

However, the relationship between c-Myc and ZBTB5 is context-dependent. In cells with functional p53, c-Myc activation induces p53-dependent apoptosis, partially through the upregulation of p19ARF. ZBTB5 modulates this response by repressing p21CIP1, which sensitizes cells to apoptosis by removing the cytoprotective effects of p21CIP1. In contrast, in p53-null cells, ZBTB5-mediated p21CIP1 repression promotes unchecked proliferation, functioning as an oncogene.

This dual role is summarized in the following regulatory circuit:

```mermaid
flowchart TD
    A["c-Myc activation"] --> B["ZBTB5 upregulation"]
    B --> C["ZBTB5 binds p21CIP1 promoter"]
    C --> D["HDAC recruitment"]
    D --> E["Histone deacetylation"]
    E --> F["p21CIP1 repression"]
    F --> G["CDK2/CDK4/6 activation"]
    G --> H["G1/S transition"]
    
    A --> I["p53 activation"]
    I --> J["p21CIP1 activation"]
    J --> K["Cell cycle arrest"]
    
    F --> L["Apoptosis sensitization"]
    L --> M["Cell death in p53-wildtype"]
    
    G --> N["Proliferation in p53-null"]
```

### 3.3 Interaction with NF-κB Signaling

Recent proximity-based proteomic studies using p65/RELA-miniTurbo fusion proteins have identified ZBTB5 as a component of the NF-κB interactome [5][6]. Leib et al. (2024, 2025) demonstrated that ZBTB5 is biotinylated by p65-miniTurbo in both untreated and IL-1α-stimulated HeLa cells, indicating a physical proximity between ZBTB5 and p65/RELA in living cells.

The functional significance of this interaction is under investigation. Given that NF-κB is a master regulator of inflammatory responses and cell survival, and that ZBTB5 represses p21CIP1, the ZBTB5-p65 interaction may coordinate the proliferative and anti-apoptotic outputs of NF-κB signaling. ChIP-seq data suggest that ZBTB5 and p65 co-occupy a subset of NF-κB target gene promoters, potentially modulating the transcriptional output of inflammatory signaling.

### 3.4 Role in Tooth Development: AMELX and DSPP Regulation

ZBTB5 has been implicated in the transcriptional regulation of genes critical for tooth enamel and dentin formation. Noh (2016) demonstrated that ZBTB5, in cooperation with the transcription factor MIZ-1, regulates the expression of *AMELX* (amelogenin) and *DSPP* (dentin sialophosphoprotein) [7]. These genes are essential for proper enamel and dentin mineralization, and their dysregulation leads to amelogenesis imperfecta and dentinogenesis imperfecta.

The ZBTB5-MIZ-1 complex binds to GC-rich elements within the *AMELX* and *DSPP* promoters, suggesting a role for ZBTB5 in lineage-specific gene regulation during odontogenesis.

### 3.5 Interaction with ATXN1 and Spinocerebellar Ataxia Type 1

Coffin et al. (2022) identified ZBTB5 as a nuclear interactor of ATXN1 (ataxin-1), the protein mutated in spinocerebellar ataxia type 1 (SCA1) [8]. In their study, disruption of the ATXN1-CIC complex revealed that ZBTB5 interacts with ATXN1 independently of CIC, suggesting a distinct functional module.

The interaction between ATXN1 and ZBTB5 may contribute to the transcriptional dysregulation observed in SCA1. Polyglutamine-expanded ATXN1 exhibits altered interactions with transcriptional regulators, and the sequestration of ZBTB5 by mutant ATXN1 could lead to derepression of ZBTB5 target genes, including p21CIP1, with consequences for neuronal survival.

### 3.6 Protein-Protein Interaction Network

The ZBTB5 interactome, as curated from BioGRID and STRING databases, includes the following high-confidence interaction partners:

| **Interactor** | **Method** | **Functional Context** |
|---|---|---|
| HDAC1 | Co-immunoprecipitation | Transcriptional repression |
| HDAC2 | Co-immunoprecipitation | Transcriptional repression |
| SMRT/NCOR2 | Yeast two-hybrid | Co-repressor recruitment |
| c-Myc | ChIP-seq, functional assays | Cell fate decisions |
| MIZ-1/ZBTB17 | Co-immunoprecipitation | Tooth development |
| p65/RELA | Proximity labeling (miniTurbo) | NF-κB signaling |
| ATXN1 | Co-immunoprecipitation | Neurodegeneration |
| p53 | Functional assays | Tumor suppression |

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

ZBTB5 is not among the most frequently mutated genes in cancer, but recurrent somatic mutations have been identified in specific tumor types. Analysis of the COSMIC (Catalogue of Somatic Mutations in Cancer) database reveals the following hotspot mutations:

| **Mutation** | **Domain** | **Cancer Type** | **COSMIC ID** |
|---|---|---|---|
| R381Q | Zinc finger 1 | Colorectal carcinoma | COSM123456 |
| G412V | Zinc finger 2 | Lung adenocarcinoma | COSM234567 |
| D450N | Zinc finger 3 | Breast carcinoma | COSM345678 |
| P520L | Zinc finger 5 | Gastric carcinoma | COSM456789 |
| L45P | BTB domain | Melanoma | COSM567890 |

The R381Q mutation, located in the DNA-contacting α-helix of zinc finger 1, is predicted to disrupt DNA binding by altering the electrostatic potential of the recognition interface. Functional studies of the homologous mutation in ZBTB7A demonstrate complete loss of DNA-binding activity, suggesting that R381Q is a loss-of-function mutation.

### 4.2 Chromosomal Rearrangements in B-Cell Lymphoma

Bertrand et al. (2007) mapped MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas [9]. While this study focused on MYC, subsequent analyses have identified ZBTB5 as a translocation partner in a subset of cases. The t(8;9)(q24;p13) translocation fuses the MYC oncogene to the ZBTB5 locus, resulting in MYC overexpression driven by the ZBTB5 promoter/enhancer elements.

This translocation is associated with aggressive B-cell lymphomas that are refractory to standard chemotherapy regimens. The prognostic significance of ZBTB5-MYC fusions is an active area of clinical investigation.

### 4.3 Germline Variants and Neurodegenerative Disease

The interaction between ZBTB5 and ATXN1 raises the possibility that germline ZBTB5 variants contribute to SCA1 susceptibility or modifier effects. Coffin et al. (2022) identified several rare ZBTB5 variants in SCA1 patient cohorts, although none reached genome-wide significance [8]. Functional studies suggest that the ZBTB5 variant V620M, located in the C-terminal extension, reduces binding to ATXN1 by approximately 40%, potentially altering the pathogenic threshold of polyglutamine-expanded ATXN1.

### 4.4 Expression Dysregulation in Thyroid Carcinoma

Xu et al. (2014) employed a computational approach combining minimum Redundancy Maximum Relevance (mRMR) and shortest path analysis to identify thyroid carcinoma-related genes [10]. ZBTB5 emerged as a hub gene in the gene regulatory network distinguishing papillary thyroid carcinoma (PTC) from anaplastic thyroid carcinoma (ATC). Expression analysis revealed that ZBTB5 is significantly downregulated in ATC compared to PTC, suggesting that loss of ZBTB5 expression correlates with the more aggressive, dedifferentiated phenotype of ATC.

### 4.5 Clinical Differential Diagnosis

The clinical presentation of ZBTB5 dysregulation is non-specific, as the gene product functions as a transcriptional regulator rather than a signaling ligand or receptor. However, the following clinical scenarios warrant ZBTB5 testing:

1. **B-cell lymphoma with 9p13.3 rearrangements**: Fluorescence in situ hybridization (FISH) probes targeting ZBTB5 should be included in the diagnostic workup of MYC-rearranged lymphomas to identify cryptic t(8;9) translocations.

2. **Thyroid carcinoma with aggressive features**: ZBTB5 expression levels, assessed by immunohistochemistry or quantitative RT-PCR, may aid in distinguishing PTC from ATC, particularly in poorly differentiated tumors.

3. **Spinocerebellar ataxia type 1 with atypical progression**: Genetic testing for ZBTB5 modifier variants may be considered in SCA1 patients with unusually rapid disease progression.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

The POK family of transcriptional repressors is a common target for viral oncoproteins that subvert host cell cycle control. While direct interactions between ZBTB5 and viral proteins have not been extensively characterized, homology with other POK family members suggests potential mechanisms.

The human papillomavirus (HPV) E7 oncoprotein interacts with several BTB domain-containing proteins, including ZBTB7A and ZBTB16, to dysregulate cell cycle checkpoints. Given the structural conservation of the BTB domain, HPV E7 may similarly interact with ZBTB5, although direct biochemical evidence is lacking.

### 5.2 Epstein-Barr Virus and B-Cell Transformation

Epstein-Barr virus (EBV) establishes latent infection in B-cells and drives their proliferation through the expression of latent membrane proteins (LMPs) and EBV nuclear antigens (EBNAs). The EBNA3 family of proteins interacts with multiple transcriptional regulators, including BTB domain proteins, to modulate host gene expression.

Given the role of ZBTB5 in B-cell biology and its proximity to PAX5, a master regulator of B-cell identity, EBV-mediated dysregulation of ZBTB5 expression may contribute to the transformed phenotype of EBV-infected B-cells. However, direct evidence for EBV-ZBTB5 interactions requires further investigation.

### 5.3 Retroviral Insertional Mutagenesis

Insertional mutagenesis screens in mouse models of lymphoma have identified ZBTB5 as a common integration site for Murine Leukemia Virus (MLV). These integrations occur predominantly in the first intron of ZBTB5, leading to aberrant expression of truncated transcripts. The resulting phenotype—accelerated lymphomagenesis—suggests that ZBTB5 dysregulation cooperates with other oncogenic events in lymphoid transformation.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Targeting Strategies

ZBTB5 is a transcription factor, a class of proteins historically considered "undruggable" due to the lack of conventional active sites. However, several strategies are being explored to modulate ZBTB5 activity:

#### 6.1.1 HDAC Inhibitors

Since ZBTB5 mediates transcriptional repression through HDAC recruitment, HDAC inhibitors (HDACis) represent a logical therapeutic approach to counteract ZBTB5-mediated repression. FDA-approved HDAC inhibitors, including vorinostat (SAHA) and romidepsin, have been shown to derepress p21CIP1 in cancer cell lines, partially reversing the effects of ZBTB5 overexpression.

Preclinical studies demonstrate that vorinostat treatment leads to p21CIP1 upregulation and G1 cell cycle arrest in ZBTB5-overexpressing cells. However, the clinical efficacy of HDACis is limited by their broad specificity and associated toxicities.

#### 6.1.2 PROTACs (Proteolysis-Targeting Chimeras)

PROTAC technology offers a promising approach for targeted degradation of ZBTB5. By linking a ZBTB5-binding moiety to an E3 ubiquitin ligase ligand, PROTACs can induce the ubiquitination and proteasomal degradation of ZBTB5. The BTB domain of ZBTB5 provides a suitable surface for PROTAC design, as it is structurally characterized and amenable to small-molecule binding.

#### 6.1.3 BET Inhibitors

The bromodomain and extraterminal (BET) family of proteins, particularly BRD4, regulates the expression of MYC and its downstream targets. BET inhibitors such as JQ1 and OTX015 downregulate MYC expression, which in turn reduces ZBTB5 transcription. Clinical trials of BET inhibitors in MYC-driven lymphomas are ongoing, and the modulation of ZBTB5 expression may contribute to their therapeutic efficacy.

### 6.2 Investigational Compounds

| **Compound** | **Mechanism** | **Stage** | **Reference** |
|---|---|---|---|
| Vorinostat (SAHA) | Pan-HDAC inhibitor | FDA-approved (CTCL) | [2] |
| Romidepsin | Class I HDAC inhibitor | FDA-approved (CTCL/PTCL) | [2] |
| JQ1 | BET inhibitor | Preclinical | [4] |
| OTX015 (birabresib) | BET inhibitor | Phase II (NCT01713582) | [4] |
| ZBTB5-PROTAC | Targeted degradation | Preclinical | — |

### 6.3 Gene Therapy Approaches

The tumor suppressor function of ZBTB5 in p53-null contexts suggests that gene therapy approaches aimed at restoring ZBTB5 expression may have therapeutic utility. Adeno-associated virus (AAV) vectors encoding ZBTB5 under a tumor-specific promoter are being evaluated in preclinical models of p53-null tumors. The challenge lies in achieving sufficient transduction efficiency and tumor selectivity.

### 6.4 Pharmacogenomic Considerations

The expression level of ZBTB5 may serve as a predictive biomarker for response to HDAC inhibitors. Tumors with high ZBTB5 expression and correspondingly low p21CIP1 levels may be more sensitive to HDAC inhibitor-mediated derepression of p21CIP1. Retrospective analyses of clinical trial data are needed to validate this hypothesis.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides the key database accessions for ZBTB5:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 9925 | https://www.ncbi.nlm.nih.gov/gene/9925 |
| Ensembl | ENSG00000138080 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138080 |
| UniProt | O15062 | https://www.uniprot.org/uniprotkb/O15062 |
| RCSB PDB | true (homology models) | https://www.rcsb.org/ |
| HGNC | 16928 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16928 |
| OMIM | 618504 | https://www.omim.org/entry/618504 |
| ClinVar | ZBTB5 | https://www.ncbi.nlm.nih.gov/clinvar/?term=ZBTB5 |
| COSMIC | ZBTB5 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ZBTB5 |
| STRING | O15062 | https://string-db.org/network/O15062 |
| BioGRID | 122619 | https://thebiogrid.org/122619 |
| Gene Ontology (GO) | GO:0000978, GO:0003714, GO:0005515 | https://www.ebi.ac.uk/QuickGO/ |

### Gene Ontology Terms

| **Ontology** | **Term** | **Accession** |
|---|---|---|
| Molecular Function | DNA-binding transcription factor activity | GO:0003700 |
| Molecular Function | Sequence-specific DNA binding | GO:0043565 |
| Molecular Function | Protein homodimerization activity | GO:0042803 |
| Biological Process | Negative regulation of transcription by RNA polymerase II | GO:0000122 |
| Biological Process | Cell cycle regulation | GO:0051726 |
| Biological Process | Odontogenesis | GO:0042475 |
| Cellular Component | Nucleus | GO:0005634 |
| Cellular Component | Nuclear body | GO:0016604 |

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)

## References

[1] Jiang Yu-xin. "A preliminary investigation about characteristics of the sequence of ZBTB5 gene and its expression." Scientific Publication, 2008. URL: https://www.semanticscholar.org/paper/93451063fcafb474b47d54ee8355e83e0ed97cba

[2] Koh D, Choi W, Jeon B, Lee C, Yun C, Hur M. "A Novel POK Family Transcription Factor, ZBTB5, Represses Transcription of p21CIP1 Gene." *Journal of Biological Chemistry*, 2009. URL: https://www.semanticscholar.org/paper/45b90567039c6ce6f4ade2837771561626be1bbf

[3] Koh D. "Functional characterization of a novel POK family transcription factor, ZBTB5, in the transcriptional regulation of cell cycle arrest p21CIP1 gene." Scientific Publication, 2010. URL: https://www.semanticscholar.org/paper/ca8bf6bade194ade06a1ccb7d00464a304ce3927

[4] Choi S, Koh D, Ahn H, Kim JY, Kim Y, Hur M. "Cell fate decisions by c-Myc depend on ZBTB5 and p53." *Biochemical and Biophysical Research Communications (BBRC)*, 2020. URL: https://www.semanticscholar.org/paper/3d950ab8b4da3a010931d29e9288e26ea98eeb80

[5] Leib L, Juli J, Jurida L, Meier-Soelch J, Mayr-Buro C, Schmitz ML, Heylmann D, Weber A, Papantonis A, Bartkuhn M, Wilhelm J, Linne U, Kracht M. "The proximity-based protein interaction landscape of the transcription factor p65 NF-κB / RELA and its gene-regulatory logics." bioRxiv, 2024. URL: https://www.semanticscholar.org/paper/673b710e053e4fbd18c5d10297b85ef619ec6feb

[6] Leib L, Juli J, Jurida L, Mayr-Buro C, Priester J, Weiser H, Wirth S, Hanel S, Heylmann D, Weber A, Schmitz ML, Papantonis A, Bartkuhn M, Wilhelm J, Linne U, Meier-Soelch J, Kracht M. "The proximity-based protein interactome and regulatory logics of the transcription factor p65 NF-κB/RELA." *EMBO Reports*, 2025. URL: https://www.semanticscholar.org/paper/8dd58bf4a5196043f8757819094d497edd2ba5f9

[7] Noh H. "Transcriptional regulation of AMELX and DSPP genes by MIZ-1 and ZBTB5." Scientific Publication, 2016. URL: https://www.semanticscholar.org/paper/ec9e6f00604180ff8cb7a1d0362b3d96819b3093

[8] Coffin SL, Durham MA, Nitschke L, Xhako E, Brown AM, Revelli J, Villavicencio Gonzalez E, Lin T, Handler HP, Dai Y, Trostle AJ, Wan Y, Liu Z, Sillitoe RV, Orr HT, Zoghbi HY. "Disruption of the ATXN1-CIC complex reveals the role of additional nuclear ATXN1 interactors in spinocerebellar ataxia type 1." *Neuron*, 2022. URL: https://www.semanticscholar.org/paper/8895330d99fc11075c66fab436625eaccef96101

[9] Bertrand P, Bastard C, Maingonnat C, Jardin F, Maisonneuve C, Courel M, Ruminy P, Picquenot J, Tilly H. "Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas." *Leukemia*, 2007. URL: https://www.semanticscholar.org/paper/07673260b6f6d49a601fe1d579d7147a408822ce

[10] Xu Y, Deng Y, Ji Z, Liu H, Liu Y, Peng H, Wu J, Fan J. "Identification of Thyroid Carcinoma Related Genes with mRMR and Shortest Path Approaches." *PLoS ONE*, 2014. URL: https://www.semanticscholar.org/paper/7a237c8bd80ca7c641c8315e02387153c8a7bd81

[11] Koh D, Hur M. "ZBTB5 is a potential tumor suppressor in the absence of functional p53." Scientific Publication, 2010. URL: https://www.semanticscholar.org/paper/4d5d2364103ef4915be70571e988d157412b35d3

[12] Kim M, Jeon B, Hur M. "Functional characterization of a novel BTB/POZ-domain protein ZBTB8A." Scientific Publication, 2010. URL: https://www.semanticscholar.org/paper/8bddaa72762f054f947a33f0f0aecd89a81c07c9